On July 2, 3SBio surged 11.78% in regular trading, reaching HK$18.38 with turnover of HK$377 million, marking a significant breakout on elevated volume.

On the news front, the company recently executed intensive share buybacks combined with management and institutional accumulation. 3SBio conducted buybacks on three consecutive trading days — June 22, 25, and 26 — repurchasing approximately 8.52 million shares for a total of approximately HK$135 million, at prices ranging from HK$15.40 to HK$16.01 per share. Additionally, Chairman and CEO Lou Jing purchased 516,000 shares on June 8 at HK$15.25 per share, while Huatianfu Fund increased its position by 636,500 shares on June 10, bringing its stake to approximately 7%.

The broader biotech sector rallied in tandem, with Kelun-Biotech up 7.75%, Innovent Biologics up 6.47%, and Akeso up 6.3%, creating a pronounced sector linkage effect that amplified buying momentum in 3SBio shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)